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Tissue products are susceptible to microbial contamination from different sources, which may 
cause disease transmission upon transplantation. Terminal sterilization using gamma 
radiation, electron-beam and ethylene oxide protocols are well-established and accepted, 
however, such methods have known disadvantages associated with compromised tissue 
integrity, functionality, safety, complex logistics, availability and cost. Non-thermal (cold) 
atmospheric pressure plasma (CAP) is an emerging technology that has several biomedical 
applications including sterilization of tissues, and the potential to surpass current terminal 
sterilization techniques. This review discusses the limitations of conventional terminal 
sterilization technologies for biological materials, and highlights the benefits of utilizing CAP. 
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Introduction  
Tissues and biological transplant materials (TBTM), including bone, soft tissues and other 
biologically-derived biomaterials should be sterilized to prevent transmission of 
microorganisms to the recipient. TBTM typically possess a natural microbial load/bioburdena 
or acquire one during collection and processing. If not eliminated, this has the potential to 
cause an infection leading to transplant failure, and further harm to the patient. Prevention of 
disease transmission is of primary concern to TBTM manufacturers and the regulatory 
authorities. 
Sterilization is the confident and reproducible elimination of all forms of life. Terminal 
sterilization is considered the final step in the manufacturing process of a sterile product in its 
final packaging.[1] Terminal sterilization is used in the processing of TBTM to provide 
sterility assurance and is generally mandated by national regulatory authorities.[2] Terminal 
sterilization is required when: TBTM are processed in non-aseptic conditions; are not treated 
by any other form of decontamination; use non-sterile consumables; or are stored in 
conditions that do not prevent microbial growth. There is no ideal sterilization process for all 
biological materials.  Each strategy faces advantages and disadvantages, requiring numerous 
considerations when choosing sterilization methods, including:  
• Material compatibility 
• Reliability against bacterial spores, endotoxins and viruses 
• Effect on production process 
• Expense 
                                                
a The term “bioburden” is used to define the number and type of bacteria and fungi present on/in a non-sterile 
product. 
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Whilst terminal sterilization destroys contaminating microbial agents, the process also 
devitalizes the cells of the tissue. As a result, terminal sterilization is unsuitable for TBTM 
that are intended to include viable and healthy donor cells. Non-viable TBTM are routinely 
used for diverse applications ranging from homotopic, long-term transplants such as bone 
grafts;[3, 4] to short-term heterotopic transplants, such as amniotic membrane (AM) which can 
be used as an ocular surface bandage.[5, 6] In these situations, terminal sterilization is 
appropriate. Preservation of the original structure and function of a tissue, both mechanically 
and biochemically is essential. However, most sterilization methods can substantially damage 
biological materials. 
Classical terminal sterilization methods such as ionizing radiation and ethylene oxide (EtO) 
have limitations including TBTM degradation, prolonged sterilization cycles, cost, logistical 
difficulties and inefficiency against viruses, prions and endotoxins. Thus, an effective 
sterilization procedure capable of maintaining a balance between sterilization efficacy, cost 
and retention of TBTM structural and functional properties is required for elimination of such 
resistant contaminants.  
Trials of non-thermal (cold) atmospheric pressure plasma (CAP) sterilization methods on 
viable cells and tissues are promising.[7-11] Whilst CAP is potentially restricted to the 
sterilization of thinner TBTM, further optimization could deliver reduced cost, time, logistics 
and damage. In contrast with conventional sterilization methods, literature has reported that 
CAP possesses the ability to eradicate all resistant contaminants such as viruses, prions, 
endotoxins and biofilm from the treated surfaces.[12, 13] 
This review compares the limitations of classic terminal sterilization of TBTM including 
gamma (γ), electron beam (e-beam) and EtO, and addresses the possibility of implementing 
CAP technologies with a particular focus on the sterilization of non-viable AM. 
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Challenges of TBTM manufacturing and risk of contamination 
Tissue processing protocols vary, depending upon tissue structure and composition and the 
intended application, which determines how well the structural and functional properties of 
the native tissue need to be maintained. Processing of TBTM may include dissection, 
intensive and prolonged washing steps to remove blood and cellular components to diminish 
the presence of antigens and disease, defatting, demineralization and decellularization. TBTM 
may be preserved dry, or in hydrated form, at ambient or cold storage conditions; they may be 
aseptically prepared, high level decontaminated, or terminally sterilized.[14] Optimized 
manufacturing procedures are crucial for the quality and safety of the final product. There are 
specified international regulatory directives set to ensure prevention of risk from 
communicable disease transmission agents during procurement, processing, preservation, 
storage and use of TBTM (Directive 2004/23/EC).[15]  
In the UK, under Human Tissue Authority (HTA) regulations, viable and non-viable tissues 
can be prepared without terminal sterilization. However, such procedures require stringent 
preparation and in-process monitoring compared with terminally sterilized tissues. Long-term 
storage of cryopreserved tissue requires specialist storage at -135 °C and with specific 
cryoprotectants such as dimethyl sulfoxide or glycerol; whereas non-viable, dehydrated 
(freeze-, heat- or vacuum-dried)  tissue can be vacuum-packed and stored at ambient 
temperature for up to 5 years.[16] 
In the US, transplantable materials such as bone, tendon, ligament, dura mater, heart valves, 
skin, cornea and AM are designated as “human cell, tissue, cellular or tissue-based products” 
(HCT/P) by the US Food and Drug Administration (FDA), with the stipulation that it is 
minimally manipulated as regulated under section 361 of the Public Health Service Act 
(PHSA) and the Code of Federal Regulations (CFR no. 21, Parts 1270 and 1271 of the FDA 
cGTP. Minimal manipulation is defined as negligible alteration to the tissues’ original 
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biological structure including physical integrity, tensile strength and elasticity; whilst 
allowing for preservation via drying, cryopreservation and denuding (removal of 
epithelium).[17] FDA regulation does not mandate terminal sterilization for HCT/Ps, however, 
aseptic processing must be used during tissue manufacturing to prevent contamination.[18]  
 
Amniotic membrane as an example of a TBTM 
AM is a TBTM that has a long history of surgical use, but has varied processing techniques 
and associated challenges. AM can be used for membrane repair on wound surfaces, or to fill 
spaces left by non-healing ulcers.[19-21] AM is commonly used in ophthalmic applications to 
treat a variety of corneal conditions.[5] Alongside acting as a transparent, physical shield, AM 
reportedly possesses protective, antimicrobial, analgesic and anti-inflammatory properties, 
that promote wound healing.[5, 6] Due to its healing properties and low immunogenicity, AM is 
often applied directly to open wounds.  
AM undergoes stringent and tightly regulated processing procedures for clinical application. 
AM is typically collected from women undergoing preplanned, full-term elective cesarean-
sections.[22] Therefore, donor screening, which involves assessment of information on health 
and social history, is the first line in disease transmission prevention. Donors must comply 
with set inclusion criteria, for example test-negative for human immune-deficiency virus 
(HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and Treponema pallidum (syphilis), 
amongst other criteria.[23, 24] 
Under normal health, AM is naturally free of bioburden whilst in the womb. However, normal 
flora of the lower genital tract (e.g. gram-positive and gram-negative aerobic and anaerobic 
organisms such as genital mycoplasmas and Streptococcus agalactiae), are capable of 
crossing intact membranes to invade the amniotic cavity during labor[25]. However, AM 
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obtained from healthy full-term cesarean sections should have no bioburden. The UK 
advisory committee on Safety of Blood, Tissues and Organs (SaBTO) guidelines state that:  
“Estimation of bioburden of skin and amnion is not recommended as the former carries a 
substantial bioburden and the latter is surgically recovered under aseptic conditions. However, 
a heavy growth of bacteria from pre-process samples may signify gross contamination and the 
tissue should not be released unless able to be terminally sterilized by irradiation or other 
techniques. The potential damage to the integrity of the tissue by the high numbers of bacteria 
should also be considered before it is used for transplantation”.[26] 
Cesarean deliveries do have the potential to introduce some contamination, likely originating 
from the donor’s skin microbial flora, transmitted during AM removal.[27, 28]  Other 
contamination may arise from the operating room environment. Further processing of AM 
usually takes place in GMP environments subjected to high-level decontamination 
procedures. AM is generally rendered non-viable during preservation, either by drying or 
freezing.[29] As a non-viable tissue, currently used surgically, AM is an ideal candidate for 
terminal sterilization. 
 
Sterilization of abnormal biological contaminants 
Processing and sterilization protocols are effective for TBTM with low to normal bioburden. 
Tissues infected with a high bioburden of endotoxin producing, gram-negative bacteria or 
virulent, antibiotic-resistant bacteria, for example pseudomonas, methicillin-resistant 
Staphylococcus aureus (MRSA) or Clostridium difficile, represent a greater hazard and are 
unsuitable for transplantation unless a terminal sterilization procedure is used, that is validated 
for effective removal or complete inactivation of microbial loads.[30] TBTM can also be 
contaminated by non-living biological agents such as endotoxins, prions and viruses, which 
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are known to resist most conventional sterilization methods.[31]  Most ISO standards exclude 
viruses and prions from their sterilization validation documents. For example, ISO 
14160:2011[32] for liquid chemical sterilization controls risks associated with only bacteria 
and fungi contamination; however, it is not applicable to TBTM. Also, ISO 11137-1:2006, for 
validation of radiation sterilization dose does not cover viral contamination and ISO 
11135:2014, for validation and control of EtO sterilization methods excludes prion 
contamination from its scope. Categorically, these standards indirectly recognize the 
downsides of industrial sterilization technologies towards particular contaminations. 
The risk of harvesting and transplanting infected tissue can be reduced, but not eliminated, by 
specific donor exclusion criteria in the form of detailed medical/social history questionnaires 
and advanced serological testing. However, terminal sterilization remains the most effective 
method for eliminating biological contamination hazards associated with donor source, 
procurement and manufacturing. Selection of the appropriate sterilization protocol for TBTMs 
must be considered on a case-by-case basis; considering the possibility of sterilization 
resistant contaminants. 
 
Endotoxins 
Endotoxins are the lipopolysaccharides (LPS) that make up the outer membranes of the 
pathogenic and non-pathogenic gram-negative bacteria.[33] Endotoxins present in the blood 
stream are life-threatening in high doses,[34] due to activation of the immune system causing 
“endotoxin shock”. Current sterilization technologies only deactivate endotoxin producing 
bacterial species and are incapable of removing endotoxins themselves. Therefore, there is 
potential endotoxin existence on sterile products. Endotoxin contamination is of great concern 
in pharmaceutical and TBTM manufacturing industries, as they are thermostable, resistant to 
pH change, vary widely in size, and have heterogeneous molecular structures.[35, 36] 
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Aggressive endotoxin removal methods such as high temperatures (250 °C for 30 min, or 180 
°C for 3 hours)[37] are unsuitable for TBTM. The terminal sterilization radiation doses 
required to degrade endotoxins are effective only at very high levels[38], which can be 
destructive to TBTM. As product removal of endotoxins is more problematic than 
sterilization; avoiding contamination by employing aseptic technique and current good tissue 
practice (cGTP) are currently the favored approach. 
 
Prions 
Prions are another challenging form of non-living contamination. They are a pathogenic form 
of misfolded protein responsible for introducing neurodegenerative disorders such as 
transmissible spongiform encephalopathies. These potentially fatal prion diseases can be 
transmitted to healthy patients through contaminated tissue allografts such dura mater and 
ocular tissue transplants.[39] Prions exhibit a resistance to most known physical and chemical 
sterilization methods. Even methods combining autoclaving with chemical treatment of 
concentrated sodium hydroxide are incapable of completely abolishing prion contamination 
from reusable hospital devices.[40] 
 
Biofilm 
A biofilm is a complex stratified mass of single or varied genotypes of microbes (bacteria or 
fungi), compacted to each other and strongly attached to surfaces. Biofilms have high 
protection capacity against disinfectants and antimicrobials compared to normal microbial 
form. Thickness and compaction determines microbial biofilm resistance to penetrating 
oxidative agents. Biofilms are formed on synthetic transplant materials[41], but are not known 
to be present on TBTM. However, biofilm presence in water pipes, channels and surfaces of 
TBTM manufacturing equipment can be a source of frequent contamination, representing a 
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considerable safety concern. Once these biofilm making microorganisms reach the 
manufacturing equipment and materials, a reliable sterilization technique is required to 
eradicate it. Examples of biofilm forming bacteria include: MRSA, Staphylococcus 
epidermidis, Staphylococcus aureus and Escherichia coli.[41] 
 
Viruses 
Non-viable TBTM that have been exposed to chemical treatment, drying or terminally 
sterilized are less virally infectious than viable tissue preserved at low temperatures.[42] 
Therefore, transmission of viruses through non-viable TBTM is rare. However, viruses with 
small, and/or double stranded genomic material have more ability to repair damage to genetic 
material than viruses with complex genomes[43], and can resist high radiation doses of 100 
kGy.[44] 
 
Established sterilization techniques for TBTM 
Challenges of TBTM manufacturing include standardization, maintenance of tissue quality 
and sterility, which may ultimately affect clinical outcome. The predominant issue with 
contemporary terminal sterilization techniques such as γ, e-beam and EtO, is maintenance of 
tissue structure and biological properties.[45] However, failure to provide sterile TBTM can 
result in significant health complications, and cost implications to health care providers. 
 
Standardization and regulation of sterilization techniques 
High temperature sterilization techniques, such as high-pressure steam methods, are 
unsuitable due to their denaturing and destructive effects on tissue extracellular matrix; they 
can also coagulate soft tissues[46] and are insufficient for endotoxin inactivation. Other non-
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thermal, conventional sterilization methods such as EtO, γ and e-beam are recognized 
techniques, which are effective when validated correctly.[40] Radiation dosage for sterilization 
is validated using ISO 11137 (2006)[47], EtO and pressured steam sterilization are also 
standardized by ISO 11135 (2007)[48] and ISO 17665-1 (2006)[49] respectively.  
The achievement of absolute sterility is difficult to determine without destructively testing all 
batch materials.[50] Therefore, sterile production standards of medical supplies, drugs and 
TBTMs refer to the sterility assurance level (SAL). SALs are based on the theoretical 
probability of overkill and demonstration of non-sterility of a particular item following 
sterilization. SAL 10-6 is adopted for medical devices and biological products and is endorsed 
by most major tissue banking societies and specialized organizations.[51, 52] Using SAL 10-6 
implies that no more than one item in one million may be non-sterile, or that there is a one in 
a million chance that an individual microbe will survive sterilization. Nevertheless, the FDA 
does not specify a particular method of terminal sterilization or a specific SAL for TBTMs. 
SAL selection is the tissue manufacturer’s responsibility and appropriate SALs lower than 10-
6 can be used if the product is unable to withstand the sterilization process (AAMI ST67 
standard). SAL 10-3 is used for inanimate medical supplies and have not been reported to be 
less assured than SAL 10-6 products in terms of preventing nosocomial infectionsb. Whilst 
current terminal sterilization techniques have revolutionized many industries including 
medicinal products and tissue supply, higher SALs may come at the cost of damaging 
TBTM.[53] 
 
Limitations of current low temperature sterilizations 
                                                
b Nosocomial infections refer to infections acquired in healthcare facilities such as hospitals that were not present 
upon administration. 
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Current terminal sterilization techniques along with their advantages and disadvantages with 
respect to TBTM are summarized in Table 1. 
Ionizing radiation sterilization at moderate doses is used at large-scale for medical supplies 
and synthetic prostheses, but there are concerns regarding their destructive effects on TBTMs 
at higher doses. γ and e-beam radiation are widely applied for tissue sterilization including 
AM.[54-57]  25 kilo gray (kGy) from both e-beam and γ sources has been internationally 
accepted as a guaranteed dose, however, the International Atomic Energy Agency (IAEA) 
standards[58] recommend a dose of below 25 kGy.[30] Conversely, concerns regarding viral 
transmission via allografts from deceased donors potentially infected with HIV/HCV/HBV 
justify higher doses (e.g. 35 kGy).[54] Debates regarding optimal sterilization dose reflect 
concerns regarding unacceptable structural damage or physicochemical changes caused by 
high radiation doses[59, 60] and irradiation cost, especially for small tissue manufacturers, is an 
additional issue.  
Chemical sterilization, such as EtO, has toxicity concerns due to high oxidative stresses of 
free radicals and residues, time-consuming processes, expense and difficult operational 
requirements. EtO sterilization unavoidably leaves residuals such as ethylene chlorohydrin 
and ethylene glycol on treated products,[61] limiting the functionality of biological tissues.[62] 
Other chemical sterilization methods, occasionally used for TBTM; are rarely regarded as 
terminal sterilization due to technical, safety or biocompatibility barriers. Super critical 
carbon dioxide (SCCO2)
[63], characterized by its efficacy against spores, penetration and 
biomaterial compatibility,[63-66] is reported to cause damage to materials, leaves residues and 
is ineffective against endotoxins. [53] [67] Vaporized peracetic acid (PAA) gas plasma, has been 
proven to have broad germicidal action over short time periods,[68] and is compatible with 
most collagenous materials and tissues.[69-71] However, PAA has time and cost constraints[72] 
and additionally, PAA sterilized ophthalmic instruments have been documented to cause 
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serious ophthalmic and skin damage with contact, leading to withdrawal from the market 
place [65, 73, 74]. Similarly, vaporized hydrogen peroxide (H2O2) gas plasma is used efficiently 
for TBTM sterilization and is FDA approved.[75, 76] However, it has problems regarding 
adverse reactions with the functional properties of the tissue and medical materials. [77, 78] 
Glutaraldehyde sterilization protocols are relatively inexpensive, effective against most 
bacteria and viruses, but limited by long process cycles and toxicity to recipient tissues and 
potentially crosslinking effects.[65]  
 
Cold atmospheric pressure gas plasma for terminal sterilization 
Plasmac has been widely investigated for medical applications in recent years. Progressive 
findings regarding the role of plasma in the deactivation and elimination of biological 
contamination demonstrates the potential for this technology to overcome the drawbacks of 
conventional sterilization methods of heat sensitive materials including TBTM. 
 
Thermal and non-thermal plasmas 
Plasmas at atmospheric pressure can be classified in terms of temperature into two categories, 
thermal[80, 81] and non-thermal.[82-84] In thermal plasma, the charged particles, neutral electrons 
and heavy particles all have the same high temperatures (in thermodynamic equilibrium with 
the surrounding temperature) and are almost fully ionized; whilst, in the non-thermal plasma 
the temperature of gas, atoms and molecules remains low[85] because of the slight ionization 
                                                
c Plasma in physics is the fourth state of matter basically constituted of partly or entirely ionized gas contains 
free radicals, charged ions and electrons, neutral atoms and other radiation.[79] 
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of the used gas[80], with only electrons at high temperature.  Due to this variation of the 
constituent’s temperature, non-thermal plasma is also termed non-equilibrium plasma.[86, 87]  
 
Low and atmospheric pressure plasmas 
Given that thermal plasma produces high gas temperature, non-thermal “cold” plasma is much 
more suitable as an emerging sterilization method[81, 86], for inactivation of microbial loads on 
human tissues and heat sensitive surfaces.[88] Furthermore, cold plasma can be produced at 
low pressures, under vacuum, but for practicality and economic reasons, it is more convenient 
and cost-effective when generated at atmospheric pressure and therefore called cold 
atmospheric-pressure plasma (CAP).[87] 
CAP is obtained by exposing gas flow (either air, or noble gases such as oxygen, nitrogen, 
argon, or helium) to a high electric field which partially ionizes the gas atoms producing a 
sustained plasma.  This plasma contains a collection of excited electrons, negative and 
positive ions, excited gas species e.g. O, O2
•, O3, OH
•, reactive oxygen species (ROS), NO 
and NO2 reactive nitrogen species (RNS), free radicals and UV-photons at different 
wavelengths.[89] These nontoxic gases become germicidal only after the plasma is ignited, 
since they are not biocidal on their own.[90] Concentration of produced plasma agents (i.e. 
ROS, RNS, UV, free radicals, charged particles) depends on the operation parameters of the 
plasma source; namely loaded gas, gas pressure, flow rate, electric voltage, etc.  
 
CAP systems 
CAP can be provided by three different systems (Figure 1): (i) Direct plasma, known as the 
dielectric barrier discharge (DBD) system. By design, the DBD system safely uses the 
material to be sterilized as a grounded electrode, which the current flows through, whilst the 
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other electrode is connected to a high voltage; air is utilized as the operating gas, and the 
distance between plasma source tip and the object is a few millimeters.[80] (ii) ‘Indirect 
plasma’, also known as atmospheric pressure plasma jet, which is deployed by a plasma 
needle/pen (narrow focused jet) or plasma torch systems which have broader streams and 
cover larger surface areas.[91] These devices generate plasma between two electrodes, 
transferred through a gas flow to the object to be treated, the distance between the object and 
the device ranges from millimeters to centimeters. The reactive species are generated by 
igniting plasma in an operating gas such as air, or by helium or argon plasmas in an admixture 
of oxygen or nitrogen.[92] (iii) Hybrid systems or coronal discharge, have characteristics of 
both direct and indirect plasmas.[80, 93]  
 
Mechanisms of microbial inactivation by CAP 
CAP technologies have been used effectively to eliminate microorganisms on living tissues in 
several clinical applications[8, 80, 94-101], including inactivation and eradication of fungi, and 
vegetative and spore-forming bacteria.[86, 89, 102] The microbial inactivation effect of CAP can 
be attained by direct exposure to both the ignited plasma discharge products such as ROS, 
RNS, UV radiation, or  indirectly through the long–lived species that are capable to reach the 
treated substrate without the electric field effect[91]. Generally, decontamination through 
plasma treatment is accomplished via oxidative stress arisen from synergetic actions of 
plasma discharge products.[88, 103]  
The specific plasma agent responsible for the mechanism of CAP killing is not clearly 
corroborated in literature[7, 89]; although CAP is proven to be damaging to bacterial cell walls, 
primarily due to ROS and RNS.[104] These charged particles have sufficient ability to induce 
high oxidative stress which cause damage in microbial cells via fast direct interactions.[81] It 
has been postulated that the accumulation of plasma charged particles over the bacterial cell 
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membrane causes membrane rupture through electrostatic disruption[105]; or that the reactive 
species permeabilize and penetrate the cell walls before reacting with DNA via complex 
mechanisms.[106] Membrane damage through lipid peroxidation is another major cause of 
bacterial death by CAP. The effect by heat and UV is argued to be indirect or negligible.[107, 
108] However, CAP’s microbicidal action produced by various plasma sources are reported to 
target viable cellular components such cell membrane, protein and DNA. The effect of CAP is 
believed overwhelming the DNA repair mechanisms of the bacterial cells.[7]   
  
 
Effects of CAP on vegetative and spore-forming bacteria 
Plasma agents destroy different microbial entities irrespective of their molecular defense 
mechanisms. Examples reported of CAP capability for decontaminating multidrug resistant 
bacteria including the highly resistant MRSA[109-111] and Pseudomonas aeruginosa.[110] 
Notably, CAP is also effective on the sterilization resistant Deinococcus radiodurans 
bacteria.[112] Less resistant vegetative bacteria have also been tested against the antimicrobial 
activity of CAP, and were eliminated with different degrees of survival, including gram-
negative: Escherichia coli[111, 113, 114], Salmonella typhimuriu [115], and gram-positive 
Staphylocuccus epidermidis
[90, 113, 116], Staphylococcus aureus[90, 114], Micrococcus luteus[95], 
Streptococcus pyogenes
[90], Enterococcus faecalis[117] and Enterococcus faecium.[90] Gram-
negative bacteria are more susceptible to gas plasma treatments than gram-positive[104, 118] and 
differences in susceptibility are thought to be due to variation in the thickness of the 
peptidoglycan murein layer in the bacterial cell wall.[86, 104]  
Skin floral bacteria Staphylococcus epidermidis is of particular importance in sterilization of 
TBTM given its frequent association with contamination from procurement and processing 
sites. It is normally found in the hair follicle where it is protected from antiseptics. CAP 
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penetration has the capacity to reach deep into hair follicles[119] and disinfect bacteria by 
94%.[120] Gram-positive skin flora Propionibacterium acnes, reported to cause post-
transplantation and implantation infection, are also effectively sterilized by CAP even in 
protected aggregated forms.[121] 
Spore-forming bacteria are typically resistant to many established sterilization protocols, and 
are often used as a model organism for sterilization verification. Studies have demonstrated 
CAP efficacy against bacterial spores, including: Bacillus subtilis, Clostridium difficile, 
Bacillus atrophaeus, Bacillus safensis, Bacillus megaterium, Bacillus megaterium 2c1 and 
Bacillus thuringiensis E24.[122, 123] Studies have shown CAP has effective sporicidal action 
even in humid conditions[124, 125], when spores are stacked together or covered by debris. 
 
Effect of CAP on abnormal contamination 
TBTM manufactured in a sterile environment using cGTP protocols are unlikely to have 
resistant contamination such as endotoxins, prions, viruses and biofilms unless a pre-
processing infection has occurred. Efficient sterilization should be able to inactivate all forms 
of disease causing contamination. The advantage of CAP sterilization compared to traditional 
methods is its powerful efficacy to eliminate resistant contamination and removal through its 
etching action, which is highly dependent upon applied plasma source. For instance, plasma 
jets have more etching capabilities than DBD systems. The plasma density, gas mixture and 
radical content are important parameters in etching of protein residues from treated surface by 
chemical degradation and volatilization mechanisms.[126] CAP has been demonstrated to be 
effective for inactivation of LPS endotoxin removal from treated surfaces within minutes.[127, 
128] Similarly, it has been shown that CAP is efficient in removing amyloid fibril aggregates 
(protein structure mimics prion) from a surfaces, and that aggregates outside the plasma 
diameter were degraded, whilst those within the plasma focus were consistently removed.[129] 
Page 16 of 41
Wiley-VCH
Plasma Processes and Polymers
For Peer Review
    
 - 17 - 
The use of a CAP system with a negative corona discharge has been shown to have a 
significant effect on prions and may reduce the infectivity of prion particles by several orders 
of magnitude.[130] This was believed to be mediated by the generated reactive particles. 
Additionally in this study, the source of CAP had different effects on the viability of brain 
cells; a positive streamer discharge killed the cells, whereas point-to-point, cometary and 
negative corona discharges did not result in a loss of cell viability. This indicates that the 
discharge configuration is an important parameter to consider when sterilizing viable tissues 
with CAP. 
TBTM contaminants such as the anaerobic gram-positive Propionibacterium acnes and 
Staphylococcus have been proven to form in vivo and in vitro biofilms, and develop resistance 
to gentamicin-loaded implants for orthopedic surgery[41], causing biomaterial/prosthesis 
transplant infection and failure.[131] Biofilms of Propionibacterium acnes bacteria have been 
found to be considerably inactivated by two types of plasma jet over short time periods.[121] 
Biofilms of MRSA, Staphylococcus epidermidis, Staphylococcus aureus and Escherichia coli 
are also removed by CAP treatment.[12] Similarly, CAP have efficiently removed biofilms of 
antifungal resistant Candida albicans.[132] This effect can potentially be enhanced by adding 
oxygen to the plasma discharge.[133] Studies have shown that viruses can be eliminated by 
CAP, due to the destruction of the protein coat, rather than a direct effect on viral DNA.[134] 
Several factors may affect the dose or the exposure time required to achieve sterilization. 
These factors are related to the plasma device operational conditions or the microorganism 
conditions before and after exposure, e.g. bacterial species, bacterial culture age (growth 
phase), bacterial medium during and post-treatment.[135] The eradicating effect of CAP on 
various microorganisms is well-established in literature [91, 130], however, studies on 
sterilization and removal of biological non-living disease causing agents would have a 
promising medical applications.[13, 130] However, CAP system variation, the flexibility of 
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utilizing variable operational conditions along with the different applications have resulted in 
complication when comparing the literature findings. Table 2 shows examples of the 
sensitivity of microorganisms of medical importance and other biological contaminants 
resistant to sterilization, treated with different CAP devices under various experimental 
conditions, with differences in exposure times and contamination reductions. CAP device 
specifications and the applied dose were omitted due to the aforementioned plasma delivery 
complexities. Often, the time required to inactivate or sterilize the microbial/biological 
contaminations is much shorter than those applied in other established sterilization methods 
regardless of the CAP system used. To achieve SAL 10-6 sterilization, exposure duration 
(plasma dose) may be extended. Therefore, it is important to have information on the level of 
initial material contamination if CAP is chosen as a sterilization protocol. It can be difficult to 
contrast and compare CAP efficacy on biological contamination due to the variability in CAP 
parameters and systems; however, this does not indicate that CAP is ineffective. 
 
Use of CAP for TBTM sterilization 
CAP has been evaluated as a safe and efficient procedure for decontamination of skin 
wounds, ulcers and infected tissues in patients, and there are commercially available products 
such as the kINPen.[136] and the DBD plasma generator (PlasmaDerm® VU-2010). [137] 
Reports often emphasize the biocompatibility of plasma treatment on viable cells and tissues, 
including ocular surface tissues. [101, 138-140] These effects are deleterious to microbial 
contamination, but have thus far not been proved to induce necrotic, apoptotic or 
morphological changes in surrounding tissues. Furthermore, no significant effects on living 
cell viability were reported.[111]  In other studies, a slight reduction in viability through 
necrosis of in vitro culture of mucosal cells was observed, however, no mutagenic effects 
were observed.[136, 141] The reason CAP mechanisms are generally harmless to human cells 
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and tissue is attributed to CAP’s superficial penetration[142]{Shintani, 2016 #459}, and 
potentially that multicellular eukaryotic tissues have more complicated mechanisms to enable 
survival of oxidative stresses introduced by plasma agents, than prokaryotic cells.[143] Limited 
penetration could be an obstacle to CAP sterilization of TBTM with thick, heterogeneous size 
and architecture such as bone graft materials.[142] However, dried, thin, soft tissues such as 
skin, facia, dura mater, AM, tendons and laminate of cartilage and bone are all candidates for 
CAP sterilization[144]. The defined advantages and disadvantages of CAP sterilization of 
TBTM are listed in Table 3.  
 
CAP as a potential technique for thin tissue sterilization 
At the time of this review there were no studies available evaluating CAP for sterilization of 
non-viable TBTM. However, if we consider non-viable AM as an example, a number of 
factors should be considered when optimizing CAP specifically, tissue thickness, treatment 
area, surface morphology, probable type and count of contamination, and whether sterilization 
will occur before or after packaging. 
A reliable sterilization method must have sufficient penetration capability. Studies have 
demonstrated that CAP delivers ROS in the range of 150 µm - 1,500 µm[145] when employed 
on a tissue-equivalent material and at over 5,000 µm for agarose gels.[101] For intact viable 
skin, reactive species can penetrate up to 10 µm depth.[136] The penetration of H2O2 produced 
by CAP into euthanized rat skin and chicken breasts was shown to go up to 4,000 µm.[146] 
Furthermore, experiments on polyester fabric materials assert that the distance from plasma 
nozzle to substrate, exposure time, and thickness of substrate, have an effect on plasma 
penetration, yet suggests longer exposure time renders a sufficient amount of reactive species 
accumulating on one side to diffuse to the other side of the porous material.[147, 148] Moreover, 
it has been demonstrated that nitric oxide (NO) generated by topical application of DBD over 
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a human skin and reconstructed epidermiswere safe on living tissue and able to penetrate and 
cause changes in microcirculation up to 6000-8000 µm on treated skin areas.[149]Dried AM 
with a thickness of approximately 20 µm[150] will therefore lie within the penetration range of 
CAP and should not require lengthy exposure times. 
Surface topography of treated tissue present challenges in sterilization, as changes can occur 
during chemical or mechanical processing, creating rough surfaces and microgrooves where 
microorganisms can reside and proliferate. Tissue surface irregularity enables contaminant 
bacteria to migrate from the surface into the tissue, protecting it from the biocidal effect of 
sterilization.[151] There are natural intercellular microholes on AM epithelial surface (Figure 
2A, B), which have been proven to allow gas transmission through dried and cryopreserved 
AM upon transplantation.[152, 153] These microholes are impermeable to bacteria such as 
Escherichia coli, Pseudomonas, Klebsiella and Staphylococcus.[154] CAP can easily reach 
narrow, confined spaces and microgrooves on surfaces.[82] and mobility of plasma gas can 
allow for treatment of microspaces[123, 155]. Recent studies reported CAP efficacy in reducing 
microbial contamination adhered to rough surfaces of chicken skin[151], titanium implant 
surfaces[156] and root canals, especially in dry state conditions.[157] This supports the 
appropriate use of CAP for sterilization of dry AM with a comparably soft homogenous 
surface (Figure 2A, C). 
Additionally, CAP treatment of large tissues requires a plasma source capable of delivering 
plasma components over wider surface areas. Single CAP jets are limited to a few 
millimeters, e.g. 25 mm2[158], thus are unsuitable, but micro-discharge plasma devices have 
been used effectively for biofilm treatment on a 177 cm2 surface area.[132] Plasma torches are 
able to treat areas of approximately 25 cm2 and DBD and jet torches appear to be favorable 
for large size membranous grafts[82] and have potential to be developed to operate as a 
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systemic scanning system for tissue materials with large surface area. The area of AM grafts 
are generally 4-100 cm2, thus CAP systems could be developed to accommodate this. 
There are parameters related to the plasma system operational conditions that will affect use, 
such as: the voltage, loaded gas, gas pressure, flow rate, exposure time and sample distance 
from plasma nozzle.[159, 160] The interplay of these parameters could yield sufficient plasma 
density and composition, or conversely might change the treatment outcome; causing 
inconsistency in sterilization cycles.[161] For instance, operational parameters such as ion and 
UV flux, electric field and gas flow might not have direct influence on the antibacterial 
efficiency, while other factors related to the method and conditions of application such as 
distance from the plasma nozzle and exposure time have a distinct influence on treatment 
efficiency.[162]  
An effective treatment that causes no damage to tissues requires a highly standardized, 
balanced and homogenous current discharge,[163] which can be attained by adjusting the 
circuit, gas flow, and power supply parameters.[88] Since varied modalities of CAP systems 
have been used as decontamination tools on different biological substrates, such as human 
skin and food products, it is possible to develop a CAP device that copes with thin non-viable 
membranous tissue sealed in sterile packaging. 
To maintain sterility of a manufactured TBTM, CAP should be applied after packaging or in-
package and sealed in a sterile environment. Use of CAP for in-package sterilization has been 
tested effective against spores, used to decontaminate foods, and is compatible with some 
packaging materials.[125, 164] DBD plasma configurations developed with efficient sporicidal 
actions were found to safely fit several shapes of Tyvek packaging materials used for sterile 
wrapping of medical instruments.[165] Different packaging materials including polyethylene, 
polypropylene and nylon loaded with microbial pathogens have shown no change in the 
physical properties after treatment with low pressure plasma.[166] Recent studies have shown 
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that generating plasma inside a closed environment can prevent post-packaging contamination 
of sterilized products.[167] 
Another attractive advantage of CAP over conventional sterilization is cost-efficiency. Cold 
plasma generators can be scaled-down as portable devices in a regular laboratory instrument 
size, for use on the bench, which suits application in small-scale tissue production.[8] Close 
proximity to tissue preparation site can potentially minimize cost of logistics and are not as 
complex as performing terminal sterilization away from the production site.  
Direct or indirect CAP systems may be appropriate for AM sterilization, as they can be 
operated at atmospheric pressure and at nearly ambient temperature[168], can deliver large 
quantities of active species with sufficient penetration power of plasma agents[81], and can 
treat reasonably large areas inside the final product packaging. Small mobile handled CAP 
devices could be an economical choice for AM sterilization inside the sterile area or 
alternately, an on-bench contained chamber design for in-package sterilization may be more 
applicable. 
 
Conclusion 
Current terminal sterilization methods such as EtO, ionizing radiation and chemical 
sterilization methods have several disadvantages including toxicity, high running-costs and 
inefficacy against abnormal contamination. CAP is a terminal sterilization technique that is 
applicable to living tissues without known harm or side effects, that has been proven to 
destroy both normal and abnormal contamination. CAP is inexpensive but limited by tissue 
thickness, post-packaging penetration and reproducibility. Choice of CAP for TBTM 
sterilization should be done on individual basis, dependent on tissue characteristics, 
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manufacturing protocol and intended use. However, if CAP can be adapted for TBTM, it 
holds a vast amount of promise. 
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Figure 1. Schematic diagram showing non-thermal, cold atmospheric pressure plasma system 
types 
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Figure 2: Scanning electron microscopy image of dried AM (A,B – epithelial side; C,D – 
stromal side). (A) Intact polygonal epithelial surface cells with occasional intracellular spaces 
(scale bar: 10 µm). (B) Box in (A) magnified to show distinct natural intracellular microholes 
(white circles) around the cell (scale bar: 1 µm). (C) Smooth regular stromal surface of AM 
(scale bar: 10 µm). (D) Collagen fibrils on the stromal side with tiny microgrooves (white 
arrows), scale bar: 1 µm)  
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Table 1. Physical and chemical terminal sterilization techniques and their advantages and 
disadvantages. 
Technique Advantages Disadvantages 
Physical: 
  
 Pressurized steam 
(autoclaving)  
 
 
Inexpensive simple, safe, rapid 
and efficient, leaves no toxic 
residues.[74] 
Easy to monitor. [40] 
 Can sterilize liquids.[40] 
 More effective than dry heat 
against prions.[40] 
 Used in both industry and clinical 
settings. 
 Incompatible with tissues and 
polymeric biomaterials due to high 
temperature and moisture that 
disrupts biochemical structures 
and causes coagulation of 
proteins.[40, 169] 
 Materials require special 
permeable packages to ensure 
steam reaches all surfaces.[40] 
 Ionizing radiation: 
 Gamma (γ) 
Radiation.  
 from 60Co 
 Effective against spore forming 
bacteria. 
 Radiation doses ≤ 25kGy do not 
alter the mechanical performance 
of soft tissues.[170]  
 Suitable for heat and moisture 
sensitive materials. 
 Higher penetration (50-80 cm).[60, 
171] 
 Dose rate approximately 10 kGy/h.  
 Immediate release after 
processing.  
 No need for permeable packaging.  
 Leaves no chemical residues or 
radioactive substances.[169, 172, 173] 
 Cost-effective compared to 
EtO.[171] 
 Predominantly only available in 
industrial and research centers.[40]  
 High capital cost for installation 
and maintenance. 
 Expensive 60Co source 
replenishment.[171] 
 Unsuitable for small tissue batch 
producers. 
 Requires high doses to deactivate 
viruses (89 kGy).  
 Higher doses than 35 kGy cause 
tissue damage.[53] 
 Causes crosslinking and/or peptide 
chain breakage.[53, 169] 
 Low dose rate (slow dose 
delivery).[60]   
 Not appropriate for viral or prion 
infected tissue.[47] 
 High doses required to eliminate 
endotoxins.[38] 
 Electron (e-beam) 
Radiation 
 Can sterilize heat and moisture 
sensitive materials, and generally 
more compatible than γ.[40] 
 Doses up to 34 kGy are less 
harmful on soft tissues.[174] 
 High dose rate (quick sterilization 
dose delivery within minutes).[60]  
 No need for permeable packaging. 
 Immediate release after 
processing.  
 High equipment  and  operational 
cost.[175] 
 Higher doses than 35 kGy 
damaging to tissues. 
 High electric consumption.[47] 
 Not appropriate virally infected 
human donated tissue grafts.[47] 
 Low penetration depth (5-8 cm).[60, 
171] 
 Not recommended for high density 
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 No chemical residues or 
radioactive substances.[169, 172, 173] 
 Cost effective compared to 
EtO.[171] 
materials.  
 Acceptable sterilization doses are 
not effective against prions. 
 Ineffective against endotoxins. 
 Chemical: 
 Ethylene Oxide 
Gas (EtO) 
 
 
 Reliable and effective 
sterilization.[176] 
 Efficient bactericidal, sporicidal 
and virucidal activity.[177] 
 Rapidly deactivates hepatitis B 
and HIV-1 viruses.[178] 
 Causes less damage to 
extracellular matrix than γ, e-beam 
and glutaraldehyde methods.[53] 
 Suitable for bulk sterilization.  
  
 Only available and suitable for 
large-scale usage. 
 High costs for small scale use.  
 Lengthy sterilization process[169, 
179]. 
 Requires special gas-permeable 
packaging.[48] 
 Recognized as a toxic waste by the 
Environmental Protection Agency 
(EPA).[61, 169, 179-181]  
 Potentially carcinogenic.[61, 182, 183] 
 Process monitoring is more 
complex than radiation, needs to 
control several parameters.[40, 184]  
 Flammable and explosive.[185] 
 Leaves toxic residues on sterilized 
materials.[169] 
 Causes potential damage to 
tissues.[61, 62, 184, 186] 
 Not recommended for sterilization 
of tissue allografts.[181, 186] 
 Danger to facility workers.[187]  
 Ineffective against prions.[48] 
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 Table 2. Examples of susceptibility of vegetative bacteria, fungi, bacterial spores, endotoxins, 
prions and biofilm to CAP treatment. 
Microorganism Importance 
Exposure 
Substrate 
Log 
reduction or 
% 
sterilization 
Exposure 
time (s) 
Ref. 
Vegetative Bacteria (gram-negative) 
Escherichia coli Clinical 
pathogen 
Agar medium 
plates 
5 log 600  [123] 
Escherichia coli Clinical 
pathogen 
Glass slides 100 % 1  [188] 
Escherichia coli 
KCTCa 1039 
Clinical 
pathogen 
Thin glass 
covers 
10 log 
100 % 
7  
60  
[122] 
Escherichia coli 
O157:H7 (C9490) 
Escherichia coli 
O157:H7 (ATCCb 
35150) 
Escherichia coli 
O157:H7 (ATCC 
43894) 
Salmonella anatum 
F4317 
Salmonella stanley 
H0558 
Salmonella enteritidis 
PT30 
Foodborne 
pathogens 
Dry almonds 1.34 log 20  [189] 
Vegetative Bacteria (gram-positive) 
Propionibacterium 
acnes KCTC 3314 
Skin flora Coated glass 
slides 
7 log 600 [121] 
Deinococcus 
radiodurans 
Radiation, 
drying and 
oxidizing 
agent resistant 
Aluminium 
discs 
3 log 1,800  [123] 
Lactobacillus 
acidophilus  
Streptococcus mutans  
Oral caries 
producing 
bacteria 
Hydroxya-
patite 
 
1.5 - 2 log 
 
6 
 
[190] 
Listeria innocua 
(ATCC 33090) 
Non- 
pathogenic 
surrogate for 
Chicken meat 
and skin 
3.3 log 480  [151] 
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 the foodborne 
pathogen  
monocytogenes 
Fungi 
Candida albicans 
(thickness of 10 - 20 
mm) 
Pathogenic 
fungus 
Polystyrene 
wafers  
9 5% 300  [133] 
Candida albicans 
Candida krusei 
Candida glabrata  
Antifungal 
resistant 
(fluconazole-
resistance) 
Air 
Water 
> 90 % 
> 90 % 
 
600  
60 
[191] 
Aspergillus flavus 
(ATCC 327)  
Aspergillus 
parasiticus (ATCC 
1041) 
Mycotoxin 
producing food 
contaminants 
Hazelnuts 4.50 log  
4.19 log  
300  [192] 
Aspergillus 
paraciticus 798 
TUBITAK-MAM  
Penicillum MS1982 
Bio-indicator 
fungus 
Vegetable and 
legumes seed 
surfaces 
3 log 900 [193] 
Spore-forming bacteria 
Bacillus subtilis  Sterilization 
resistant  
Thin glass 
covers 
10 log 
100 % 
24  
120  
[122] 
Bacillus safensis, 
DSMc 19292T 
Bacillus megaterium, 
ATCC 14581T 
Bacillus megaterium 
DSM 30587 (2c1)  
Sterilization 
resistant 
Aluminium 
discs 
˃ 6 log 
100% 
3,600 
5,400  
[123] 
Bacillus atrophaeus 
DSM675 
Bacillus thuringiensis 
DSM 30879 (E24) 
Sterilization 
resistant 
Aluminium 
discs 
˃ 3 log 
 
 
5,400 [123] 
Bacillus subtilis  Sterilization 
resistant  
Glass slide & 
aluminium 
substrates 
4 log (He 
plasma) 
8 log (air 
plasma) 
˂ 600  [194] 
 
Bacillus atrophaeus Biological 
indicator for 
thermal 
sterilization 
Commercial 
spore strip 
≥ 6 log10 60  [125] 
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(Heat resistant) 
Endotoxins 
LPS from Escherichia 
Coli  ATCC 8739  
Pyrogen Glass slides 100 % 10  [188] 
Viruses 
Adenovirus, non-
enveloped double 
stranded DNA virus 
Human 
infectious 
disease 
causing 
PBS Solution 6 log 240  [13] 
Bacteriophage lambda 
(λ phage) 
Virus that 
infects bacteria 
Buffer 6 log 20  [134] 
Bacteriophage lambda 
(λ phage) C-17 
(ATCC 23724-B1) 
Lytic bacteriophage 
(Rambo; Microphage) 
 
Virus that 
infects bacteria 
NAd 4–6 log 600 [196] 
MS2 bacteriophage 
ATTC 15597-B1  
Surrogate of 
human enteric 
viruses such as 
norovirus that 
causes 
infectious 
gastroenteritis 
Phage 
suspension 
4.98 -7.06 log 450 [197] 
Influenza virus type A 
(H5N2) 
Human parainfluenza 
virus type 3 strain C-
243 ATCC VR-93 
Respiratory syncytial 
virus-A ATCC VR-26 
Airborne 
respiratory 
pathogen 
Viral aerosol 
suspension 
4 log (99.20 
%) 
6.5 log (99.22 
%) 
3.8 log (99.00 
%) 
180 [198] 
Prions 
Scrapie (Rocky 
Mountain Laboratory 
strain, RML5)  
 
Surrogate of 
human prion 
1% mouse 
brain in PBS 
solution 
100 % 600-1,200 [130] 
Biofilm 
Pseudomonas 
aeruginosa SG81, 
 
Clinical 
pathogen 
Polycarbonate 
discs. 
4.83 log 
7.11 log 
300 
600 
[118] 
Staphylococchus Skin flora Polycarbonate 2.77 log 300 [118] 
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epidermidis RP62A discs 3.38 log 600 
Salmonella enterica 
serovar typhimurium  
Listeria 
monocytogenes  
Escherichia coli 
Enterococcus faecalis 
Clinical 
pathogens 
Lettuce 5 log 300  [199] 
Candida albicans Clinical 
pathogen 
Inanimate 
surface 
6 log 240  [132] 
 
a)KCTC= Korean Collection for Type Cultures, Korea; b)ATCC= American Type Culture 
Collection, USA; c)DSM= Leibnitz Institute DSMZ-German Collection of Microorganism and 
Cell Cultures, Germany;    d)NA= not available 
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Table 3. Advantages and disadvantages of CAP sterilization of TBTM 
Advantages Disadvantages 
Biocompatible with viable and non-viable 
tissues. 
Methods not yet validated.  
No toxic chemical residue left on treated 
object.[136] 
Low penetration power so may be not 
suitable for thick TBTM materials.[142] 
Shorter exposure time than established 
sterilization methods (seconds to minutes). 
Difficult to apply to packaged materials. 
No toxic effects to operators and the 
environment.[200] 
Not validated as terminal sterilization that 
offers SAL of 10-6. 
Can remove bacterial cells and viruses from 
sterilized surfaces. 
Many parameters (e.g. loaded gas, gas 
pressure, flow rate, voltage, exposure time 
and sample distance) need to be controlled 
to get the desired capacity of charged 
species. 
Effective on endotoxins, prions and 
bacterial and fungal biofilms.[132] 
 
Delivers uniform treatment to uneven 
surfaces of biological materials.[201] 
 
CAP gas capable of reaching confined and 
narrow spaces.[82] 
 
Microorganism resistance to CAP is 
unlikely to occur.[106] 
 
Inexpensive.[202]  
Can be used portably or in smaller scale 
(such as in laminar flow hoods and 
isolators).[202] 
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